| Last: 0.30 | Day Low: 0.28 | Volume: 28000 |  |
| Change: 0.00 | Day High: 0.30 | Date: 5/17/2012 |
Mar 28, 2012
iCo Therapeutics and JDRF Team Up
to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema
Enter Your Email to Sign Up for
iCo Therapeutics Updates
iCo Therapeutics Updates
Welcome to iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol “ICO”.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO".
